This protein carries no "tag".
The protein has a calculated MW of 19.2 kDa. As a result of glycosylation, the protein migrates as 24 kDa (monomer) under reducing (R) condition, and 43-50 kDa (homodimer) under non-reducing (NR) condition (SDS-PAGE).
>98% as determined by SDS-PAGE.
>95% as determined by SEC-MALS.
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.
ActiveMax® Human VEGF165, Tag Free (MALS verified) on SDS-PAGE under reducing (R) and non-reducing (NR) conditions. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 98%.
The purity of ActiveMax® Human VEGF165, Tag Free (MALS verified) (Cat. No. VE5-H4210) was more than 95% in HP-SEC, and around 40-55 kDa verified by SEC-MALS.
Immobilized ActiveMax® Human VEGF165, Tag Free (MALS verified) (Cat. No. VE5-H4210) at 0.01 μg/mL (100 μL/well) can bind Human VEGF R1, His Tag (Cat. No. VE1-H5220) with a linear range of 4-31 ng/mL (QC tested).
Immobilized ActiveMax® Human VEGF165, Tag Free (MALS verified) (Cat. No. VE5-H4210) at 2 μg/mL (100 μL/well) can bind pre-mixed increasing concentrations of Bevacizumab and 0.5 μg/mL (100 μL/well) Biotinylated Human VEGF R2, Avitag,His Tag (Cat. No. KDR-H82E5) with a half maximal inhibitory concentration (IC50) of 0.70 μg/mL (Routinely tested).
Avastin (Bevacizumab) captured on CM5 chip via anti-human IgG Fc antibodies surface, can bind ActiveMax® Human VEGF165, Tag Free (MALS verified) (Cat. No. VE5-H4210) with an affinity constant of 0.776 nM as determined in a SPR assay (Biacore T200) (Routinely tested).
Loaded Avastin (Bevacizumab) on AHC Biosensor, can bind ActiveMax® Human VEGF165, Tag Free (MALS verified) (Cat. No. VE5-H4210) with an affinity constant of 0.016 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
ActiveMax® Human VEGF165, Tag Free (MALS verified) (Cat. No. VE5-H4210) stimulates proliferation of human umbilical vein endothelial cells (HUVEC). The ED50 for this effect is 4.216-9.281 ng/mL (Routinely tested).
Inhibition assay shows that the proliferation effect of ActiveMax® Human VEGF165, Tag Free (MALS verified) (Cat. No. VE5-H4210) is inhibited by increasing concentration of anti-VEGF mAb (Avastin). The concentration of VEGF165 used is 20 ng/mL. The ED50 is 0.065-0.229 μg/mL (Routinely tested).
Authors: Stumpf C, et al
Journal: PLoS One 2020
Application: eBRET2 biosensors
Authors: ML Wetter, et al
Journal: US20180354997A1 43447
Authors: Keys TG, et al.
Journal: Metab Eng 2017
Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.
Price(USD) : $220.00
Price(USD) : $335.00
Price(USD) : $2000.00
High quality SARS-CoV-2 S protein, S1 protein and human ACE2 protein based on the human cell expression platform of HEK293.
ACROBiosystems has developed a series of homogeneous CD3 proteins with good bioactivity. They are verified as 1:1 heterodimers by nonreductive electrophoresis and MALS as well.
ACRO screened a few different beads and bring this tightly controlled superparamagnetic microspheres to you. This product can be widely applied for immunocapture, bio panning and flow cytometry.
ACROBiosystems has developed a series of kit products using its high-quality SARS-CoV-2 antigen proteins to improve the efficiency of anti-SARS-CoV-2 drugs and vaccines development.
This web search service is supported by Google Inc.